Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Protalix BioTherapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix's partner in "the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system", issued a press release "acknowledging that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve the dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio (pegunigalsidase alfa, in addition to the currently approved dosing regimen of 1 mg/kg body weight infused every 2 weeks (E2W)." Following this news, Protalix's stock price fell over 22% on October 17, 2025.
In order to be eligible to join the PLX class action lawsuit, you must have incurred a loss on shares of Protalix BioTherapeutics, Inc. purchased during the class period listed above.
TOP
